Erica DiNapoli

Erica DiNapoli is an Assistant Editor for OncLive®. She joined the company in 2020 and now assists in editing and publishing both videos and informational articles to the website; she also helps manage the social media platforms. Prior to joining MJH Life Sciences, she was a student at Monmouth University and held two marketing internships at United Teletech Financial Federal Credit Union and Trendsetter Media & Marketing.

Articles

Chasing Survival Benefit With Novel Systemic Strategies in Early-Stage NSCLC

March 11th 2021

Kaushal Parikh, MD, MBBS, highlights ongoing research exploring systemic approaches in early-stage non¬–small cell lung cancer and shares where future efforts are headed.

Nanoliposomal Irinotecan Possesses Potential to Shake Up Pancreatic Cancer Paradigm

February 19th 2021

Reema A. Patel, MD, discusses the potential for nanoliposomal irinotecan in pancreatic cancer and other emerging approaches under exploration.

Grothey Spotlights Personalized Approaches Shaking Up CRC Care Continuum

February 10th 2021

Axel Grothey, MD, highlights recent advancements in CRC treatment, including innovative combinations and emerging agents that are generating excitement in the field.

Hanhan Highlights How Robotic Techniques Have Shifted Surgical Care in Lung Cancer

February 4th 2021

Ziad Hanhan MD, MPH, FACS, highlights the evolution of surgery in the field of lung cancer, the advantages associated with robotic techniques, and the crucial role of the surgeon in determining eligibility for these approaches.

Metastatic Prostate Cancer Paradigm Flourishes With Recent Progress

February 1st 2021

Data from 3 pivotal trials—PROfound, CARD, and HERO—have served to propel the metastatic prostate cancer treatment paradigm forward.

BTK Combos Seek to Raise the Bar in CLL Treatment Paradigm

January 27th 2021

Tara Graff, DO, highlights active areas of exploration that are generating excitement in chronic lymphocytic leukemia.

Hormonal Agents Improve Survival in mCSPC, but Novel Targets Are Needed For Further Drug Development

January 26th 2021

Neeraj Agarwal, MD, discusses the role of docetaxel in the frontline setting, the emergence of novel hormonal agents in the paradigm, and efforts being made with combination regimens to potentially treat patients with resistant disease.

Parsaclisib Yields Encouraging Clinical Activity in Marginal Zone Lymphoma

January 21st 2021

Tycel Phillips, MD, highlighted the key findings of the phase 2 CITADEL-204 trial.

1-Year DFS Rates Similar Between Ibrutinib and Placebo Following Ibrutinib/Venetoclax in CLL

January 21st 2021

William G. Wierda, MD, PhD, discusses the latest CAPTIVATE findings in patients with chronic lymphocytic leukemia.

Emerging Strategies Seek to Build on Radiation Benefits in Lung Cancer

January 19th 2021

Katie Keane, MD, highlights the evolving role of stereotactic body radiation therapy in the treatment of patients with stage I lung cancer, the utilization of immunotherapy with chemoradiation in stage III disease, and research evaluating radiation in those with oligometastatic disease.

Stadtmauer Spotlights the Explosion of BCMA-Directed Therapies in Multiple Myeloma

January 14th 2021

Edward A. Stadtmauer, MD, highlights the emergence of several BCMA-directed therapies, such as monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies, and how outcomes for patients with multiple myeloma have improved significantly.

Aggressive Treatment Approaches Expected to Move Dial in Metastatic Colon Cancer

January 13th 2021

Michael J. Cavnar, MD, highlights the role of surgery in colon cancer, the role of tumor sidedness in informing surgical decisions, and research efforts that are being done to evaluate the utility of hepatic artery infusion pumps.

Addition of Darolutamide May Augment Standard Treatment for Localized, Very High-Risk Prostate Cancer

January 11th 2021

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the benefit achieved with standard-of-care radiation therapy plus androgen deprivation therapy with a luteinising hormone-releasing hormone analogue.

Need for Molecular Testing in Lung Cancer Is Underscored as Additional Targets Emerge

January 8th 2021

Yujie Zhao, MD, PhD, highlights molecular testing and how it's a critical component of the treatment selection process in lung cancer, as a host of effective drugs have since been developed to target alterations such as ALK, ROS1, and RET.

Mobile Intervention for Adherence to Aromatase Inhibitors Misses Mark in Breast Cancer

January 4th 2021

Julie Gralow, MD, discusses exciting research in HER2-positive breast cancer.

Hunt for Predictive Biomarkers for T-DM1 in HER2+ Breast Cancer Continues

January 4th 2021

Ian E. Krop, MD, PhD, highlights the impact of the pivotal KATHERINE trial on the adjuvant treatment of patients with early-stage HER2-positive breast cancer and other recent advances that are moving the needle forward.

Role for Somatic, Inherited Genetic Testing in Prostate Cancer Continues to Grow

January 3rd 2021

Leonard G. Gomella, MD, discusses the growing importance of genetic testing in prostate cancer.

Expert Compares Open vs Robotic Radical Cystectomy Approaches in Muscle Invasive Bladder Cancer

January 2nd 2021

Bryon Lee, MD, PhD, discusses recent advances in surgical technique, approach, and perioperative care have made radical cystectomy significantly less morbid for patients with muscle invasive bladder cancer.

Matching Novel Targets to Treatment Generates Excitement in TNBC

December 31st 2020

Neelima Vidula, MD, discusses the current and future utility of PARP inhibitors in triple-negative breast cancer, the promise of sacituzumab govitecan, and the need for germline genetic testing.

Emergence of Encouraging Biomarkers in TNBC Provide Potential for Personalized Care

December 30th 2020

Debra Patt, MD, highlights recent advancements and novel approaches in triple-negative breast cancer.